Switch to:
Also traded in: Canada, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.37
NEPT's Cash-to-Debt is ranked lower than
90% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. NEPT: 0.37 )
Ranked among companies with meaningful Cash-to-Debt only.
NEPT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.77 Max: No Debt
Current: 0.37
Equity-to-Asset 0.59
NEPT's Equity-to-Asset is ranked lower than
60% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NEPT: 0.59 )
Ranked among companies with meaningful Equity-to-Asset only.
NEPT' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.42  Med: 0.55 Max: 0.83
Current: 0.59
-0.42
0.83
Interest Coverage 1.33
NEPT's Interest Coverage is ranked lower than
98% of the 453 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NEPT: 1.33 )
Ranked among companies with meaningful Interest Coverage only.
NEPT' s Interest Coverage Range Over the Past 10 Years
Min: 0  Med: 0 Max: 1.33
Current: 1.33
0
1.33
Piotroski F-Score: 4
Altman Z-Score: 0.99
Beneish M-Score: 2.45
WACC vs ROIC
6.09%
6.32%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % 6.95
NEPT's Operating Margin % is ranked higher than
77% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. NEPT: 6.95 )
Ranked among companies with meaningful Operating Margin % only.
NEPT' s Operating Margin % Range Over the Past 10 Years
Min: -262.75  Med: -35.28 Max: 6.95
Current: 6.95
-262.75
6.95
Net Margin % 13.96
NEPT's Net Margin % is ranked higher than
84% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. NEPT: 13.96 )
Ranked among companies with meaningful Net Margin % only.
NEPT' s Net Margin % Range Over the Past 10 Years
Min: -185.54  Med: -32.98 Max: 13.96
Current: 13.96
-185.54
13.96
ROE % 11.54
NEPT's ROE % is ranked higher than
88% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. NEPT: 11.54 )
Ranked among companies with meaningful ROE % only.
NEPT' s ROE % Range Over the Past 10 Years
Min: -596.63  Med: -35.71 Max: 11.54
Current: 11.54
-596.63
11.54
ROA % 6.28
NEPT's ROA % is ranked higher than
87% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. NEPT: 6.28 )
Ranked among companies with meaningful ROA % only.
NEPT' s ROA % Range Over the Past 10 Years
Min: -34.21  Med: -15.56 Max: 6.28
Current: 6.28
-34.21
6.28
ROC (Joel Greenblatt) % 5.28
NEPT's ROC (Joel Greenblatt) % is ranked higher than
78% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. NEPT: 5.28 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NEPT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -80.32  Med: -32.38 Max: 5.28
Current: 5.28
-80.32
5.28
3-Year Revenue Growth Rate -14.60
NEPT's 3-Year Revenue Growth Rate is ranked lower than
71% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. NEPT: -14.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NEPT' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -8 Max: 30.5
Current: -14.6
0
30.5
3-Year EBITDA Growth Rate -30.10
NEPT's 3-Year EBITDA Growth Rate is ranked lower than
81% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. NEPT: -30.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NEPT' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -34.4  Med: -2.7 Max: 219.3
Current: -30.1
-34.4
219.3
3-Year EPS without NRI Growth Rate -31.40
NEPT's 3-Year EPS without NRI Growth Rate is ranked lower than
80% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. NEPT: -31.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NEPT' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -48.9  Med: 11.3 Max: 200
Current: -31.4
-48.9
200
GuruFocus has detected 3 Warning Signs with Neptune Technologies & Bioressources Inc $NEPT.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NEPT's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

NEPT Guru Trades in

NEPT Guru Trades in

NEPT Guru Trades in

Q2 2015

NEPT Guru Trades in Q2 2015

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NEPT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 3741
Compare:OTCPK:MCUJF, OTCPK:RNUGF, OTCPK:MTFBF, NAS:AKTX, OTCPK:ORGS, NAS:LIFE, NAS:BLRX, AMEX:ATNM, NAS:VCEL, NAS:VSTM, NAS:NOVN, NAS:SVRA, NAS:NTEC, NAS:AGLE, NAS:AVEO, OTCPK:CYDY, NAS:OPHT, NAS:CYTR, NAS:NVET, OTCPK:PTGEF » details
Traded in other countries:NEPT.Canada, NTU.Germany,
Headquarter Location:Canada
Neptune Technologies & Bioressources Inc is a nutrition company. The Company is engaged in the development, manufacture and commercialization of marine‐derived omega‐3 polyunsaturated fatty acids from Antarctic krill.

Neptune Technologies & Bioressources Inc was incorporated on October 9, 1998. It is a biotechnology company engaged in the development, manufacture and commercialization of marine derived omega polyunsaturated fatty acids. It is engaged in the research, development and commercialization of products derived from marine biomasses for the nutraceutical and pharmaceutical industries. The Company has three segments structured in three distinctive legal entities: the first is producing and commercializing nutraceutical products (Neptune); development and commercialization of pharmaceutical products for cardiovascular diseases applications (Acasti); and development and commercialization of pharmaceutical products for neurological diseases applications (NeuroBioPharm). The Company produces omega 3 PUFAs through its patented process of extracting oils from Antartic krill, which omega 3 PUFAs are then sold as bulk oil to company's distributors who commercialize them under their private label in the U.S., European and Australian nutraceutical markets. Its products include Neptune Krill Oil and ECOKRILL Oil generally come in capsule form and serves as a dietary supplement to consumers.

Top Ranked Articles about Neptune Technologies & Bioressources Inc

Neptune and Enzymotec Reach Patent Agreement Ending All Litigation
Neptune to Hold Conference Call to Discuss First Quarter Results for the Period Ended May 31, 2016

LAVAL, QUEBEC--(Marketwired - Jun 30, 2016) - Neptune Technologies & Bioressources Inc. ("Neptune" or the "Company") (NASDAQ:NEPT)(TSX:NTB), announces that it will be holding a conference call on July 12, 2016 at 8:00 AM (EST) to discuss its first quarter results for the period ended May 31, 2016. The first quarter results press release will be issued after markets close on July 11, 2016. Conference Call Details:



Date:
Tuesday, July 12, 2016






Time:
8:00 AM Eastern Standard Time






Call:
1‐877-223-4471 (within Canada & the U.S.)



1-647-788-4922 (Outside Canada and the U.S.)



(Please dial in 15 minutes before the call begins)






Webcast:
A live audio webcast can be accessed at:



http://neptunekrilloil.com/investors/investor-events-and-presentations/



A replay of the call will be available until August 12, 2016. The telephone numbers to access the replay of the call are 1-416-621-4642 or 1-800-585-8367 (toll-free), Conference ID 44177587. The replay of the conference call will also be made available in the Investors section of Neptune's website under Investor Events and Presentations, in the days following the event. About Neptune Technologies & Bioressources Inc. Neptune is a nutrition company that develops, manufactures, and globally commercializes marine-derived omega-3 polyunsaturated fatty acids (PUFA's) from Antarctic krill. More recently, with the acquisition of Biodroga, the company also provides innovative custom-made nutraceutical finished products from marine oils, and various other functional ingredients often in unique delivery forms. Neptune's head office is located in Laval, Quebec. Neptune is also pursuing opportunities in the prescription drug markets, through its approximately 48% owned subsidiary Acasti Pharma Inc. ("Acasti"). Acasti focuses on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment of severe hypertriglyceridemia.





Neptune Contact:
Mario Paradis
VP & CFO
1.450.687.2262
[email protected]
www.neptunebiotech.com
Pierre Boucher
MaisonBrison
1.514.731.0000
[email protected]




Read more...
Neptune Announces Fourth Quarter and Fiscal Year Results

Positive Forward Momentum Continues

LAVAL, QUEBEC--(Marketwired - May 25, 2016) - Neptune Technologies & Bioressources Inc. (NASDAQ:NEPT)(TSX:NTB) Q4 Financial and Operational Highlights (1):

Revenues of $10.0 million, up 161% versus last year
Gross margin on sales rose to 27%
Nutraceutical segment generated positive Adjusted EBITDA of $658,000 compared to a loss of $7.8 million a year ago
Q4 closing cash balance of $3.5 million
Realized 50% of $5.0 million cost savings plan
Canada now one of only two countries that can export krill oil to China opening new opportunities
Neptune receives first Chinese orders

Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation"), today announced its financial and operating results for the fourth quarter and fiscal year ended February 29, 2016. All amounts are in Canadian dollars. "For the past 12 months, we were pleased to deliver sequential quarter-over-quarter improvements in the Nutraceutical segment leading to a positive Adjusted EBITDA in the fourth quarter," stated Jim Hamilton, President and CEO of Neptune. The financial contribution and integration of Biodroga is well on track, supporting our strategy to move up the value chain as we create a more diversified nutrition products company with fast growing market opportunities." "Despite certain competitive supply and consumer demand headwinds in North America and Australia with regards to the Krill business, we have significantly improved our operations and manufacturing cost base in Fiscal 2016. We are excited about the recent approval to sell krill oil in the Chinese market, and received our first orders for that large and fast growing market." "In Fiscal 2017, we expect significant growth in revenues and Adjusted EBITDA for the Nutraceutical segment considering the acquisition and overall operating efficiencies. At this time, for the Nutraceutical segment, we expect revenue to be greater than the last twelve month Fiscal 2016 Revenues proforma of $41 million and a double digit Adjusted EBITDA margin assuming constant currencies," concluded Mr. Hamilton. Productivity Initiatives Driving Margin Improvements Project Turbo, a company-wide initiative to drive efficiencies and operating performance, was put in place during the second quarter of Fiscal 2016. To date (as of February 29, 2016), approximately 50% of total expected cost savings, or approximately $5.0 million, were realized. (1) Neptune Nutraceutical segment Nutraceutical Business Results

Nutraceutical revenues were $10.0 million for the three-month period ended February 29, 2016, versus $3.8 million in the fourth quarter ended February 28, 2015.
Adjusted EBITDA(2) was $658,000 for the current quarter, compared to a Non-IFRS operating loss of $7.8 million in the prior year. This represents the first quarter of positive EBITDA since 2012.
Net income was $963,000 for the current quarter, versus a net loss of $9.1 million in the prior year.
Nutraceutical revenues were $23.0 million for the year ended February 29, 2016, versus $15.0 million for the year ended February 28, 2015.
Non-IFRS operating loss was $4.6 million for the year ended February 29, 2016, improving over $24.5 million for the corresponding prior-year period.
Net loss was $6.8 million for the year ended February 29, 2016, improving over a net loss of $30.6 million for the corresponding prior-year period.

(2) See "Caution Regarding Non-IFRS Financial Measures" which follows The Nutraceutical segment fourth quarter EBITDA improvement was mainly driven by higher revenues and a stronger gross margin related to cost reduction initiatives, including plant efficiencies and the Biodroga acquisition contribution. The net income reflects stronger revenues, a significant gross margin improvement, along with the recognition of deferred tax assets. In comparison, the prior year net loss included plant ramp-up costs. "We ended Fiscal 2016 with a cash balance $3.5 million. On April 20th, we announced a term loan financing of $4 million that could reach up to $10 million under certain conditions. For the first quarter of Fiscal 2017, we expect revenues of approximately $11 million and another positive Adjusted EBITDA for our Nutraceutical segment. We have the funds in place to support our growth strategy and we anticipate that our results will improve significantly year-over-year," indicated Mario Paradis, Vice President and Chief Financial Officer. Update on Acasti Pharma Inc, a 48% owned subsidiary of Neptune (For more information, see separate press release issued today) On May 12, 2016, Ms. Jan D'Alvise was appointed President and Chief Executive Officer of Acasti Pharma Inc. effective June 1, 2016. Ms. D'Alvise is an accomplished executive with experience in large, public multi-national companies, as well as in private start-ups in the life sciences industry. Her exceptional track-record includes leadership roles across the enterprise life-cycle, from start-up to commercialization and growth. Ms. D'Alvise has established strategic partnerships of substantial value and secured significant financing through institutional investors. On December 16, 2015, Acasti announced that it had made important progress in its correspondence with the US Food and Drug Administration (FDA) regarding next steps in the development plans for CaPre®. "As planned, we initiated and recently completed subject enrollment for the bioavailability bridging study," highlighted Pierre Lemieux, PhD, Acasti's Chief Operating Officer. "We are expecting results of the study before the end of the year which should confirm our chosen regulatory pathway." Consolidated Results

Consolidated revenues totalled $10.0 million for the three-month period ended February 29, 2016, up from $4.0 million for the quarter ended February 28, 2015.
Non-IFRS operating loss of $493,000 for the current quarter, versus $10.0 million in the prior year.
Net loss was $379,000 for the current quarter, versus a net loss of $10.7 million in the prior year.
Consolidated revenues totalled $22.6 million for the year ended February 29, 2016, compared to $15.1 million for the corresponding prior-year period.
Non-IFRS operating loss of $11.2 million for the year ended February 29, 2016, versus $32.9 million for the corresponding prior-year period.
Net loss was $10.8 million for the year ended February 29, 2016, versus a net loss of $29.8 million in the corresponding prior-year period.

On a consolidated basis, the current quarter includes a Non-IFRS operating loss of $1.2 million and a net loss of $1.9 million for Neptune's subsidiary, Acasti, which is actively engaged in clinical studies and research and development. In the corresponding prior year quarter ending February 28, 2015, Acasti recorded a Non-IFRS operating loss of $2.3 million and a net loss of $2.3 million. Cash Flows Consolidated cash and short term investments were $13.0 million as at February 29, 2016, including

$10.5 million for Acasti. The Corporation also has restricted short-term investments of $3.0 million as at February 29, 2016. Caution Regarding Non-IFRS Financial Measures
The Corporation uses adjusted financial measures, including Adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) and non-IFRS operating loss (Operating loss before depreciation and amortization), to assess its operating performance. These non-IFRS financial measures are directly derived from the Company's financial statements and are presented in a consistent manner. The Company uses these measures for the purposes of evaluating its historical and prospective financial performance, as well as its performance relative to competitors. These measures also help the Company to plan and forecast for future periods as well as to make operational and strategic decisions. The Company believes that providing this information to investors, in addition to IFRS measures, allows them to see the Company's results through the eyes of management, and to better understand its historical and future financial performance. Securities regulations require that companies caution readers that earnings and other measures adjusted to a basis other than IFRS do not have standardized meanings and are unlikely to be comparable to similar measures used by other companies. Accordingly, they should not be considered in isolation. The Corporation uses Adjusted EBITDA and non-IFRS operating loss to measure its performance from one period to the next without the variation caused by certain adjustments that could potentially distort the analysis of trends in our operating performance, and because the Corporation believes it provides meaningful information on the Corporation financial condition and operating results. Neptune's method for calculating Adjusted EBITDA or non-IFRS operating loss may differ from that used by other corporations. Neptune obtains its Consolidated Adjusted EBITDA and non-IFRS operating loss measurement by adding to net income (loss), finance costs, depreciation and amortization and income taxes and by subtracting finance income. Other items such as insurance recoveries from plant explosion and acquisition costs that do not impact core operating performance of the Corporation are excluded from the calculation as they may vary significantly from one period to another. Finance income/costs include foreign exchange gain (loss) and change in fair value of derivatives. Neptune also excludes the effects of certain non-monetary transactions recorded, such as stock-based compensation, acquisition costs and insurance recoveries, from its Adjusted EBITDA and non-IFRS operating loss calculation. The Corporation believes it is useful to exclude this item as it is a non-cash expense. Excluding this item does not imply it is necessarily non-recurring. Conference Call Details Neptune will be holding a conference call on May 26, 2016 at 8:30 AM (ET) to present its results for the fourth quarter and fiscal year ended February 29, 2016.


Date:
Thursday May 26, 2016






Time:
8:30 AM Eastern Time






Conference ID:
11355723






Call:
1‐877-223-4471 (within Canada & the U.S.)



1-647-788-4964 (Outside Canada and the U.S.)



(Please dial in 15 minutes before the call begins)






Webcast:
A live audio webcast can be accessed at:



http://neptunekrilloil.com/investors/investor-events-and-presentations/



An archived recording of the conference call will also be available on Neptune's website shortly after the call. About Neptune Technologies & Bioressources Inc. Neptune is a nutrition company that develops, manufactures, and globally commercializes marine-derived omega-3 polyunsaturated fatty acids (PUFA's) from Antarctic krill. More recently, with the acquisition of Biodroga, the company also provides innovative custom-made nutraceutical finished products from marine oils, and various other functional ingredients often in unique delivery forms. Neptune's head office is located in Laval, Quebec. Neptune is also pursuing opportunities in the prescription drug markets, through its approximately 48% owned subsidiary Acasti Pharma Inc. ("Acasti"). Acasti focuses on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment of severe hypertriglyceridemia. Forward Looking Statements Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the U.S. securities laws and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of Neptune to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement and the "Cautionary Note Regarding Forward-Looking Information" section contained in Neptune's latest Annual Information Form (the "AIF"), which also forms part of Neptune's latest annual report on Form 40-F, and which is available on SEDAR at www.sedar.com, on EDGAR at www.sec.gov/edgar.shtml and on the investor section of Neptune's website at www.neptunebiotech.com. All forward-looking statements in this press release are made as of the date of this press release. Neptune does not undertake to update any such forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in Neptune public securities filings with the Securities and Exchange Commission and the Canadian securities commissions. Additional information about these assumptions and risks and uncertainties is contained in the AIF under "Risk Factors". Neither NASDAQ nor the Toronto Stock Exchange accepts responsibility for the adequacy or accuracy of this release.


Reconciliation of net income (loss) to Adjusted EBITDA or non-IFRS operating loss



(Expressed in thousands of dollars)





Three-month period ended February 29, 2016




Nutraceutical

Cardiovascular

Inter-segment

eliminations

Total




$

$

$

$



Adjusted EBITDA (non-IFRS operating loss) calculation










Net income (loss)
963

(1,919
)
577

(379
)


Add (deduct):











Depreciation, amortization and impairment loss
760

950

(581
)
1,129




Finance costs
474

(1
)
(27
)
446




Finance income
36

(175
)
27

(112
)



Change in fair value of derivative financial instruments
5

(114
)
4

(105
)



Stock-based compensation
247

108

-

355




Tax credits recoverable
(152
)
-

-

(152
)



Income taxes
(1,928
)
-

-

(1,928
)



Acquisitions costs
253

-

-

253



Adjusted EBITDA (non-IFRS operating loss)
658

(1,151
)
-

(493
)














Year ended February 29, 2016




Nutraceutical

Cardiovascular

Inter-segment eliminations

Total




$

$

$

$



Non-IFRS operating loss calculation










Net loss
(6,765
)
(6,317
)
2,252

(10,830
)


Add (deduct):











Depreciation, amortization and impairment loss
2,652

2,734

(2,323
)
3,063




Finance costs
1,471

2

(27
)
1,446




Finance income
(357
)
(1,096
)
27

(1,426
)



Change in fair value of derivative financial instruments
72

(2,201
)
71

(2,058
)



Stock-based compensation
1,331

309

-

1,640




Insurance recoveries
(1,224
)
-

-

(1,224
)



Tax credits recoverable
(152
)
-

-

(152
)



Income taxes
(1,928
)
-

-

(1,928
)



Acquisitions costs
253

-

-

253



Non-IFRS operating loss
(4,647
)
(6,569
)
-

(11,216
)




















Neptune Contact:
Mario Paradis
VP & CFO
1.450.687.2262
[email protected]
www.neptunebiotech.com
Pierre Boucher
MaisonBrison
1.514.731.0000
[email protected]




Read more...

Ratios

vs
industry
vs
history
PE Ratio 15.11
NEPT's PE Ratio is ranked higher than
82% of the 240 Companies
in the Global Biotechnology industry.

( Industry Median: 28.38 vs. NEPT: 15.11 )
Ranked among companies with meaningful PE Ratio only.
NEPT' s PE Ratio Range Over the Past 10 Years
Min: 12.8  Med: 23.73 Max: 965
Current: 15.11
12.8
965
PE Ratio without NRI 15.11
NEPT's PE Ratio without NRI is ranked higher than
82% of the 234 Companies
in the Global Biotechnology industry.

( Industry Median: 29.63 vs. NEPT: 15.11 )
Ranked among companies with meaningful PE Ratio without NRI only.
NEPT' s PE Ratio without NRI Range Over the Past 10 Years
Min: 12.8  Med: 25.43 Max: 99999999.99
Current: 15.11
12.8
99999999.99
PB Ratio 1.85
NEPT's PB Ratio is ranked higher than
80% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. NEPT: 1.85 )
Ranked among companies with meaningful PB Ratio only.
NEPT' s PB Ratio Range Over the Past 10 Years
Min: 1.55  Med: 5.38 Max: 37.8
Current: 1.85
1.55
37.8
PS Ratio 2.60
NEPT's PS Ratio is ranked higher than
85% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. NEPT: 2.60 )
Ranked among companies with meaningful PS Ratio only.
NEPT' s PS Ratio Range Over the Past 10 Years
Min: 1.56  Med: 8.27 Max: 34.17
Current: 2.6
1.56
34.17
EV-to-EBIT 42.83
NEPT's EV-to-EBIT is ranked lower than
75% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. NEPT: 42.83 )
Ranked among companies with meaningful EV-to-EBIT only.
NEPT' s EV-to-EBIT Range Over the Past 10 Years
Min: -223.9  Med: -14 Max: 1664.6
Current: 42.83
-223.9
1664.6
EV-to-EBITDA 21.64
NEPT's EV-to-EBITDA is ranked lower than
54% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. NEPT: 21.64 )
Ranked among companies with meaningful EV-to-EBITDA only.
NEPT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -767.2  Med: -16.95 Max: 762.2
Current: 21.64
-767.2
762.2
PEG Ratio 0.25
NEPT's PEG Ratio is ranked higher than
95% of the 101 Companies
in the Global Biotechnology industry.

( Industry Median: 2.13 vs. NEPT: 0.25 )
Ranked among companies with meaningful PEG Ratio only.
NEPT' s PEG Ratio Range Over the Past 10 Years
Min: 0  Med: 6.38 Max: 69.98
Current: 0.25
0
69.98
Current Ratio 2.07
NEPT's Current Ratio is ranked lower than
73% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. NEPT: 2.07 )
Ranked among companies with meaningful Current Ratio only.
NEPT' s Current Ratio Range Over the Past 10 Years
Min: 0.4  Med: 2.67 Max: 5.93
Current: 2.07
0.4
5.93
Quick Ratio 1.32
NEPT's Quick Ratio is ranked lower than
79% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. NEPT: 1.32 )
Ranked among companies with meaningful Quick Ratio only.
NEPT' s Quick Ratio Range Over the Past 10 Years
Min: 0.2  Med: 1.91 Max: 4.87
Current: 1.32
0.2
4.87
Days Inventory 173.27
NEPT's Days Inventory is ranked lower than
64% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. NEPT: 173.27 )
Ranked among companies with meaningful Days Inventory only.
NEPT' s Days Inventory Range Over the Past 10 Years
Min: 58.23  Med: 195.73 Max: 318.25
Current: 173.27
58.23
318.25
Days Sales Outstanding 117.17
NEPT's Days Sales Outstanding is ranked lower than
76% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. NEPT: 117.17 )
Ranked among companies with meaningful Days Sales Outstanding only.
NEPT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 77.93  Med: 115.96 Max: 159.39
Current: 117.17
77.93
159.39

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -9.10
NEPT's 3-Year Average Share Buyback Ratio is ranked higher than
57% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. NEPT: -9.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NEPT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -30.5  Med: -14.8 Max: -6.2
Current: -9.1
-30.5
-6.2

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 2.59
NEPT's Price-to-Tangible-Book is ranked higher than
75% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. NEPT: 2.59 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
NEPT' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.38  Med: 6.99 Max: 42.54
Current: 2.59
2.38
42.54
Price-to-Median-PS-Value 0.32
NEPT's Price-to-Median-PS-Value is ranked higher than
89% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. NEPT: 0.32 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
NEPT' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.12  Med: 0.97 Max: 12
Current: 0.32
0.12
12
Price-to-Graham-Number 1.33
NEPT's Price-to-Graham-Number is ranked higher than
79% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 2.64 vs. NEPT: 1.33 )
Ranked among companies with meaningful Price-to-Graham-Number only.
NEPT' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.21  Med: 2.2 Max: 8.39
Current: 1.33
1.21
8.39
Earnings Yield (Greenblatt) % 2.32
NEPT's Earnings Yield (Greenblatt) % is ranked higher than
76% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. NEPT: 2.32 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
NEPT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.1  Med: 2.4 Max: 2.7
Current: 2.32
0.1
2.7

More Statistics

Revenue (TTM) (Mil) $33.92
EPS (TTM) $ 0.07
Beta0.44
Short Percentage of Float7.07%
52-Week Range $0.91 - 1.53
Shares Outstanding (Mil)77.95

Analyst Estimate

Feb17 Feb18 Feb19 Feb20
Revenue (Mil $) 36 40 43 46
EPS ($) -0.02 0.04 0.05 0.06
EPS without NRI ($) -0.02 0.04 0.05 0.06
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NEPT

Headlines

Articles On GuruFocus.com
Neptune and Enzymotec Reach Patent Agreement Ending All Litigation Apr 03 2017 
Acasti Pharma Reports Second Quarter 2017 Financial Results Oct 11 2016 
Neptune and Ingenutra Sign an Exclusive Worldwide Agreement for MaxSimil® Oct 07 2016 
Neptune and Aker BioMarine Reach Important Patent Agreement, Recognizing the Patents' Strength and E Oct 03 2016 
Neptune to Hold Conference Call to Discuss Second Quarter Results for the Period Ended August 31, 20 Sep 28 2016 
NEPTUNE Introduces NKO(R) Omega Plus, a New and Innovative Krill Oil Product with one of the Highest Sep 15 2016 
Acasti Pharma Reports Positive CaPre Omega-3 Bridging Study Data Sep 15 2016 
Neptune to Hold Conference Call to Discuss First Quarter Results for the Period Ended May 31, 2016 Jun 30 2016 
Neptune Announces Fourth Quarter and Fiscal Year Results May 25 2016 
Acasti Announces Fourth Quarter and Fiscal Year Results May 25 2016 

More From Other Websites
Neptune to Hold Conference Call to Discuss Fourth Quarter and Fiscal Year-End Results for the... May 18 2017
Acasti Pharma Presents CaPre Clinical Data at National Lipid Association Scientific Sessions May 18 2017
Unique Medical Cannabis Partnership Announced, Creating Scientific and Business Development Hub in... May 16 2017
Acasti Granted Additional Composition & Use Patents in Taiwan and Australia; Safeguards Valuable... Apr 24 2017
Acasti Pharma to Present CaPre Omega-3 Bridging Study Results at National Lipid Association... Apr 12 2017
Neptune enters into Commercial Distribution Joint Venture in China with Shanghai Chonghe Marine... Apr 05 2017
Neptune and Enzymotec Reach Patent Agreement Ending All Litigation Apr 03 2017
Neptune and Enzymotec reach Patent Agreement Ending All Litigation Apr 03 2017
Acasti Pharma Forms Scientific Advisory Board and Appoints Two Leading Cardiovascular Disease... Mar 08 2017
Acasti Pharma Grants Incentive Stock and Options Feb 24 2017
Neptune to Present at ROTH Capital Partners 29th Annual Growth Stock Conference Feb 22 2017
Acasti Pharma Announces Proposed Private Placement of Convertible Debentures and Amended Proposed... Feb 02 2017
Neptune Technologies & Bioresources, Inc. :NEPT-US: Earnings Analysis: Q3, 2017 By the Numbers :... Jan 18 2017
Neptune Tech posts 3Q profit Jan 12 2017
Acasti Pharma Reports Third Quarter 2017 Financial Results Jan 12 2017
Neptune Announces Record Third Quarter Results Jan 12 2017
Neptune to Hold Conference Call to Discuss Third Quarter Results for the Period Ended November 30,... Jan 04 2017
Validity of Neptune's Patent Upheld by Australian Patent Office Nov 07 2016
Neptune Announces Stock Ticker Symbol Change to NEPT on the TSX Nov 04 2016
Acasti Announces Stock Ticker Symbol Change to ACST on the TSXV Nov 03 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}